Skip to main content
. 2015 Mar 13;32(3):270–283. doi: 10.1007/s12325-015-0193-5

Fig. 3.

Fig. 3

FAERS and MarketScan® adverse event rate ratios and 95% confidence intervals for levetiracetam during the post-generic entry period. FAERS Food and Drug Administration Adverse Event Reporting System